Cargando…

Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99–411, with long acting prescription antimalarials, lumefantrine and piperaquine

The pharmacokinetic compatibility of short-acting CDRI candidate antimalarial trioxane derivative, 99–411, was tested with long-acting prescription antimalarials, lumefantrine and piperaquine. LC-ESI-MS/MS methods were validated for simultaneous bioanalysis of lumefantrine and 99–411 and of piperaqu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taneja, Isha, Raju, Kanumuri Siva Rama, Singh, Sheelendra Pratap, Wahajuddin, Muhammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658560/ https://www.ncbi.nlm.nih.gov/pubmed/26602250 http://dx.doi.org/10.1038/srep17264

Ejemplares similares

Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97–78 in rat plasma using the HPLC–ESI-MS/MS method: application to drug interaction study
por: Wahajuddin, Muhammad, et al.
Publicado: (2015)

Assay method for quality control and stability studies of a new antimalarial agent (CDRI 99/411)()
por: Khandelwal, Kiran, et al.
Publicado: (2013)

DBS-platform for biomonitoring and toxicokinetics of toxicants: proof of concept using LC-MS/MS analysis of fipronil and its metabolites in blood
por: Raju, Kanumuri Siva Rama, et al.
Publicado: (2016)

Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats
por: Singh, Yeshwant, et al.
Publicado: (2014)

Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats
por: Wahajuddin, et al.
Publicado: (2011)

No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in rats
por: Raju, Kanumuri Siva Rama, et al.
Publicado: (2015)

Novel series of 1,2,4-trioxane derivatives as antimalarial agents
por: Rudrapal, Mithun, et al.
Publicado: (2017)

Electrocardiographic effect of artemisinin-piperaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine treatment in falciparum malaria patients
por: Wu, Wanting, et al.
Publicado: (2021)

Solvent and Substituent Effects on the Thermolysis of Antimalarial Fluorophenyl Substituted 1,2.4-Trioxanes
por: Cafferata, Lazaro F. R., et al.
Publicado: (2003)

In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum
por: Dormoi, Jérome, et al.
Publicado: (2014)

Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination
por: Gerardin, Jaline, et al.
Publicado: (2015)

Pharmacokinetic Study and Bioavailability of a Novel Synthetic Trioxane Antimalarial Compound 97/63 in Rats
por: Kushwaha, Hari Narayan, et al.
Publicado: (2014)

Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation
por: Funck-Brentano, Christian, et al.
Publicado: (2019)

Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug
por: Shafiq, N., et al.
Publicado: (2014)

Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial
por: Kamya, Moses R, et al.
Publicado: (2007)

Plasmodium berghei ANKA: Selection of resistance to piperaquine and lumefantrine in a mouse model
por: Kiboi, D.M., et al.
Publicado: (2009)

Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
por: Staehli Hodel, Eva Maria, et al.
Publicado: (2013)

The Knockout for G Protein-Coupled Receptor-Like PfSR25 Increases the Susceptibility of Malaria Parasites to the Antimalarials Lumefantrine and Piperaquine but Not to Medicine for Malaria Venture Compounds
por: Santos, Benedito M., et al.
Publicado: (2021)

Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold
por: Rudrapal, Mithun, et al.
Publicado: (2016)

Mechanistic Evaluation of the Stability of Arylvinyl-1,2,4-trioxanes under Acidic Conditions for Their Oral Administration as an Antimalarial Drug
por: Kumari, Akriti, et al.
Publicado: (2022)

Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine
por: Permala, Jesmin, et al.
Publicado: (2017)

Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model
por: Gimode, Winnie R, et al.
Publicado: (2015)

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects
por: Green, Justin A., et al.
Publicado: (2016)

Efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated malaria in Papua New Guinea
por: Tavul, Livingstone, et al.
Publicado: (2018)

Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
por: Assefa, Ashenafi, et al.
Publicado: (2022)

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials
por: Norcross, Neil R., et al.
Publicado: (2016)

Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area
por: Song , Jianping, et al.
Publicado: (2011)

Correction: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
por: Assefa, Ashenaf, et al.
Publicado: (2023)

Efficacy of Quinine, Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine as Rescue Treatment for Uncomplicated Malaria in Ugandan Children
por: Yeka, Adoke, et al.
Publicado: (2013)

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling
por: Hodel, Eva Maria, et al.
Publicado: (2014)

High therapeutic efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Somalia
por: Warsame, Marian, et al.
Publicado: (2019)

Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
por: Pascual, Aurélie, et al.
Publicado: (2012)

Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
por: Katrak, Shereen, et al.
Publicado: (2009)

Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities
por: Whitty, Christopher JM, et al.
Publicado: (2008)

Fixed Dose Combination of Arterolane and Piperaquine: A Newer Prospect in Antimalarial Therapy
por: Patil, CY, et al.
Publicado: (2014)

Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand
por: Tarning, J, et al.
Publicado: (2014)

Gas chromatographic method for the determination of lumefantrine in antimalarial finished pharmaceutical products
por: Suleman, Sultan, et al.
Publicado: (2015)

PM411. Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
por: Brown, Brianne, et al.
Publicado: (2016)

Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in Uganda
por: Yeka, Adoke, et al.
Publicado: (2008)

Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children
por: Nambozi, Michael, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_c8563olprm7rjrrrcj2koa49nu